This activity is for healthcare professionals outside of the UK.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    Download Practice Aid
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Sherko Kümmel

    Kliniken Essen-Mitte, Essen, Germany

    Prof. Sherko Kümmel is the clinical director and chairman of the Interdisciplinary Breast Unit Clinics of Essen-Mitte in Germany, where he also leads the Breast Cancer Research Programme. read more

    Prof. Kümmel has been the principal investigator for many national and international phase I–III clinical trials. As a member of the Independent Data Monitoring Committee (IDMC), Prof. Kümmel has participated in several national and international steering committees, including involvement in the steering committee, protocol group or Independent Data Monitoring Committee of 74 national and international clinical trials.

    In addition to his work at the Essen-Mitte clinics, Prof. Kümmel is an executive board member of the Gynaecological Oncology Working Group (AGO); a speaker for the AGO Commission for Integrative Medicine (AGIMed); a member of the AGO organ commission (AGO Mamma); and a scientific director of the West German Study Group (WSG), an academic study group for breast cancer (BC). He is also a faculty member of the European Society for Medical Oncology (ESMO) and a member of the ESMO Scientific Committee.

    Prof. Kümmel has published extensively on BC surgery and treatment and has co-authored over 378 publications and 78 books and chapters. As a renowned speaker, Prof. Kümmel has presented over 412 congress abstracts and proceedings and given more than 1,300 presentations and lectures.

    Prof. Sherko Kümmel discloses: Advisory board/panel fees from Agendia, Amgen, AstraZeneca, Daiichi Sankyo, Exact Science, Gilead Sciences, Lilly, MSD, Novartis, Pfizer, pfm medical, Roche, Seagen and Sonoscape. Consultancy fees from Lilly, MSD and Stryker. Speakers’ bureau fees from Agendia, Amgen, AstraZeneca, Daiichi Sankyo, Exact Science, Gilead Sciences, Hologig, Lilly, MSD, Novartis, Pfizer, pfm medical, PINKI Pharma, Roche, Seagen, Somatex and Stemline. Data safety monitoring fees from Agendia, Amgen, AstraZeneca, Daiichi Sankyo, Exact Science, Gilead Sciences, Lilly, MSD, Novartis, Pfizer, pfm medical, Roche, Seagen and Sonoscape. Other fees from Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and WSG.
    Prof. Rebecca Dent

    National Cancer Center Singapore, Singapore

    Prof. Rebecca Dent is deputy chief executive officer (clinical) at the National Cancer Center Singapore (NCCS) at SingHealth and a senior consultant in the breast medical oncology service, as well as a professor at Duke-NUS Medical School. read more

    Prof. Dent’s main research interest is in the field of breast cancer (BC), focusing specifically on early, large operable, locally advanced and metastatic triple-negative BC (TNBC). Recognizing the need for a pan-Asian regional educational interaction, Prof. Dent co-founded and co-chaired nine Asia Pacific BC Summits. This is a multidisciplinary meeting, which attracts over 2,000 attendees from over 25 countries. She is a global principal investigator and/or steering committee member for a number of large international trials in TNBC, which have been cited more than 15,000 times, and an h-index of 49.

    Prof. Dent has served on a number of prominent international committees, such as the American Society of Clinical Oncology (ASCO) Scientific Committee (ER/HER2 track), education chair of the Breast Track ASCO Annual Meeting, editorial board member of the Journal of Clinical Oncology, scientific chair of European Society of Medical Oncology (ESMO) Asia, chair of the ESMO Metastatic Breast Track, Scientific Committee member of ASCO Breakthrough Asia and, more recently, editorial board member of The Lancet Oncology (Impact Factor: 54).

    She is most proud to be the recipient of the ESMO Women for Oncology Award 2021 and was elected to serve on the Nomination Committee from 2021 to 2023, whose main responsibility is to select the next ESMO President. In 2024, she received the Duke-NUS Master Academic Clinician award and she served as the scientific chair for the ESMO Congress at Barcelona.

    Prof. Rebecca Dent discloses: Advisory board or panel feels from AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly & Company, Genentech, Gilead Sciences, MSD, Novartis, Pfizer and Roche. Grants/research support from AstraZeneca and Roche.
    Prof. Peter Schmid

    Barts Cancer Institute, London, UK

    Prof. Peter Schmid is the clinical director of the Breast Cancer (BC) Centre and an honorary consultant medical oncologist at St. Bartholomew’s Hospital. He is the chair in Cancer Medicine at Barts Cancer Institute (BCI), Queen Mary University London, and leads the Centre of Experimental Cancer Medicine at BCI, overseeing the conduct of early phase trials at St. Bartholomew’s Hospital and BCI. He also leads the Academic BC Programme at St. Bartholomew’s Hospital and BCI. read more

    Prof. Schmid’s research interests focus on improving the care of women with BC through clinical trials. He has led a spectrum of clinical trials ranging from phase I to III, spanning the spectrum of the disease. The majority of these studies are translational phase II studies investigating novel targeted and immunotherapies. Current interests include cancer immunotherapy combinations across all stages and subtypes of BC; novel targeted agents and antibody–drug conjugates, alone or in combination to overcome resistance; and innovative biomarker-driven trial concepts (including a preoperative window of opportunity platform to evaluate novel immunotherapy combinations in BC). His work has been published in many journals, including the New England Journal of Medicine, The Lancet, The Lancet Oncology and JAMA Oncology, among others.

    Prof. Schmid is a member of several national and international cancer organizations and research groups, and he has been involved in international consensus meetings on the management of BC. He is a member of the European Society for Medical Oncology (ESMO) BC faculty.

    Prof. Peter Schmid discloses: Consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Merck, Novartis, Pfizer, Puma and Roche. Grants/research support from Astellas, AstraZeneca, Genentech, Medivation, Merck, Novartis, Oncogenex and Roche.
    Back to Faculty
    touchONCOLOGY touchONCOLOGY
    SEE ALL VIDEOS
    Start activity

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    What is your main challenge with maximizing the benefit of immunotherapy?

    Submit your answer to see the results

    Managing high-grade irAEs
       
    Managing low-grade irAEs
       
    IO rechallenge post-irAE
       
    MDT collaboration
       

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    Which factor do you consider most important to optimize biomarker testing?

    Submit your answer to see the results

    Timing of testing
       
    Testing using primary or metastatic tissue
       
    Use of validated, standardized assays
       
    Availability/quality of tissue sample
       

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    In your opinion, what is the greatest unmet need in the treatment of patients with early-stage TNBC?

    Submit your answer to see the results

    Lack of standard-of-care for stage I TNBC
       
    Reliable biomarkers to guide treatment selection
       
    More effective therapies to reduce recurrence risk
       
    Other
       
     
    Expert Interviews
    Breast Cancer, Immunotherapy CE/CME accredited

    touchEXPERT FOCUS
    Three experts answer questions on a specific theme offering practical insights drawn from daily practice. Close

    Multidisciplinary management of TNBC: Integrating immunotherapies for early and metastatic disease

    Take CE/CME Test

    Prof. Sherko Kümmel is the clinical director and chairman of the Interdisciplinary Breast Unit Clinics of Essen-Mitte in Germany, where he also leads the Breast Cancer Research Programme. read more

    Prof. Kümmel has been the principal investigator for many national and international phase I–III clinical trials. As a member of the Independent Data Monitoring Committee (IDMC), Prof. Kümmel has participated in several national and international steering committees, including involvement in the steering committee, protocol group or Independent Data Monitoring Committee of 74 national and international clinical trials.

    In addition to his work at the Essen-Mitte clinics, Prof. Kümmel is an executive board member of the Gynaecological Oncology Working Group (AGO); a speaker for the AGO Commission for Integrative Medicine (AGIMed); a member of the AGO organ commission (AGO Mamma); and a scientific director of the West German Study Group (WSG), an academic study group for breast cancer (BC). He is also a faculty member of the European Society for Medical Oncology (ESMO) and a member of the ESMO Scientific Committee.

    Prof. Kümmel has published extensively on BC surgery and treatment and has co-authored over 378 publications and 78 books and chapters. As a renowned speaker, Prof. Kümmel has presented over 412 congress abstracts and proceedings and given more than 1,300 presentations and lectures.

    Prof. Sherko Kümmel discloses: Advisory board/panel fees from Agendia, Amgen, AstraZeneca, Daiichi Sankyo, Exact Science, Gilead Sciences, Lilly, MSD, Novartis, Pfizer, pfm medical, Roche, Seagen and Sonoscape. Consultancy fees from Lilly, MSD and Stryker. Speakers’ bureau fees from Agendia, Amgen, AstraZeneca, Daiichi Sankyo, Exact Science, Gilead Sciences, Hologig, Lilly, MSD, Novartis, Pfizer, pfm medical, PINKI Pharma, Roche, Seagen, Somatex and Stemline. Data safety monitoring fees from Agendia, Amgen, AstraZeneca, Daiichi Sankyo, Exact Science, Gilead Sciences, Lilly, MSD, Novartis, Pfizer, pfm medical, Roche, Seagen and Sonoscape. Other fees from Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and WSG.

    Take CE/CME Test

    Prof. Rebecca Dent is deputy chief executive officer (clinical) at the National Cancer Center Singapore (NCCS) at SingHealth and a senior consultant in the breast medical oncology service, as well as a professor at Duke-NUS Medical School. read more

    Prof. Dent’s main research interest is in the field of breast cancer (BC), focusing specifically on early, large operable, locally advanced and metastatic triple-negative BC (TNBC). Recognizing the need for a pan-Asian regional educational interaction, Prof. Dent co-founded and co-chaired nine Asia Pacific BC Summits. This is a multidisciplinary meeting, which attracts over 2,000 attendees from over 25 countries. She is a global principal investigator and/or steering committee member for a number of large international trials in TNBC, which have been cited more than 15,000 times, and an h-index of 49.

    Prof. Dent has served on a number of prominent international committees, such as the American Society of Clinical Oncology (ASCO) Scientific Committee (ER/HER2 track), education chair of the Breast Track ASCO Annual Meeting, editorial board member of the Journal of Clinical Oncology, scientific chair of European Society of Medical Oncology (ESMO) Asia, chair of the ESMO Metastatic Breast Track, Scientific Committee member of ASCO Breakthrough Asia and, more recently, editorial board member of The Lancet Oncology (Impact Factor: 54).

    She is most proud to be the recipient of the ESMO Women for Oncology Award 2021 and was elected to serve on the Nomination Committee from 2021 to 2023, whose main responsibility is to select the next ESMO President. In 2024, she received the Duke-NUS Master Academic Clinician award and she served as the scientific chair for the ESMO Congress at Barcelona.

    Prof. Rebecca Dent discloses: Advisory board or panel feels from AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly & Company, Genentech, Gilead Sciences, MSD, Novartis, Pfizer and Roche. Grants/research support from AstraZeneca and Roche.

    Take CE/CME Test

    Prof. Peter Schmid is the clinical director of the Breast Cancer (BC) Centre and an honorary consultant medical oncologist at St. Bartholomew’s Hospital. He is the chair in Cancer Medicine at Barts Cancer Institute (BCI), Queen Mary University London, and leads the Centre of Experimental Cancer Medicine at BCI, overseeing the conduct of early phase trials at St. Bartholomew’s Hospital and BCI. He also leads the Academic BC Programme at St. Bartholomew’s Hospital and BCI. read more

    Prof. Schmid’s research interests focus on improving the care of women with BC through clinical trials. He has led a spectrum of clinical trials ranging from phase I to III, spanning the spectrum of the disease. The majority of these studies are translational phase II studies investigating novel targeted and immunotherapies. Current interests include cancer immunotherapy combinations across all stages and subtypes of BC; novel targeted agents and antibody–drug conjugates, alone or in combination to overcome resistance; and innovative biomarker-driven trial concepts (including a preoperative window of opportunity platform to evaluate novel immunotherapy combinations in BC). His work has been published in many journals, including the New England Journal of Medicine, The Lancet, The Lancet Oncology and JAMA Oncology, among others.

    Prof. Schmid is a member of several national and international cancer organizations and research groups, and he has been involved in international consensus meetings on the management of BC. He is a member of the European Society for Medical Oncology (ESMO) BC faculty.

    Prof. Peter Schmid discloses: Consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Merck, Novartis, Pfizer, Puma and Roche. Grants/research support from Astellas, AstraZeneca, Genentech, Medivation, Merck, Novartis, Oncogenex and Roche.

    Take CE/CME Test
    Faculty Podcast Featured
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Review the latest data and guideline recommendations for treating early-stage TNBC with immunotherapy approaches and their implications for clinical practice
    • Summarize considerations for treating metastatic TNBC with immunotherapy approaches, including the latest data, guideline recommendations and the application of biomarker testing
    • Evaluate practical strategies for maximizing the benefit of immunotherapy approaches in TNBC with effective management of immune-related adverse events and multidisciplinary, patient-centred care
    Overview

    In these short interviews, three renowned experts in breast cancer (BC) share their insights on the latest data and guideline recommendations for using immunotherapy (IO) in early-stage and metastatic triple-negative BC (TNBC), and share strategies for maximizing the benefit of IO approaches through effective management of immune-related adverse events and multidisciplinary, patient-centred care.

    This activity is jointly provided by USF Health and touchIME. read more

    Target Audience

    This activity has been designed to meet the educational needs of medical oncologists, surgical oncologists, physician assistants, oncology nurses, nurse practitioners and nurse navigators.

    USF Accreditation

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty

    Prof. Sherko Kummel discloses: Advisory board/panel fees from Agendia, Amgen, AstraZeneca, Daiichi Sankyo, Exact Science, Gilead Sciences, Lilly, MSD, Novartis, Pfizer, pfm medical, Roche, Seagen and Sonoscape. Consultancy fees from Lilly, MSD and Stryker. Speakers’ bureau fees from Agendia, Amgen, AstraZeneca, Daiichi Sankyo, Exact Science, Gilead Sciences, Hologig, Lilly, MSD, Novartis, Pfizer, pfm medical, PINKI Pharma, Roche, Seagen, Somatex and Stemline. Data safety monitoring fees from Agendia, Amgen, AstraZeneca, Daiichi Sankyo, Exact Science, Gilead Sciences, Lilly, MSD, Novartis, Pfizer, pfm medical, Roche, Seagen and Sonoscape. Other fees from Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and WSG.

    Prof. Rebecca Dent discloses: Advisory board or panel feels from AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly & Company, Genentech, Gilead Sciences, MSD, Novartis, Pfizer and Roche. Grants/research support from AstraZeneca and Roche.

    Prof. Peter Schmid discloses: Consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Merck, Novartis, Pfizer, Puma and Roche. Grants/research support from Astellas, AstraZeneca, Genentech, Medivation, Merck, Novartis, Oncogenex and Roche.

    Content Reviewer

    Danielle Walker, DNP, APRN, AGNP-C has no financial interests/relationships or affiliations in relation to this activity.

    touchIME Medical Contributor

    Katrina Lester has no financial interests/relationships or affiliations in relation to this activity.

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu.

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Date of original release: 25 June 2025. Date credits expire: 25 June 2026.

    If you have any questions regarding credit please contact cpdsupport@usf.edu.

    Nurses

    USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    A maximum of 0.75 contact hour(s) may be earned by learners who successfully complete this continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.

    This activity is awarded 0.75 ANCC pharmacotherapeutic contact hour.

    Date of original release: 25 June 2025. Date credits expire: 25 June 2026.

    If you have any questions regarding credit please contact cpdsupport@usf.edu. 

    EBAC® Accreditation

    touchIME is an EBAC® accredited provider since 2023.

    This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 49 minutes of effective education time.

    EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

    Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

    EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

    Faculty Disclosure Statement / Conflict of Interest Policy

    In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.

    Requirements for Successful Completion

    Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.

    Date of original release: 25 June 2025. Date credits expire: 25 June 2027.

    Time to complete: 49 minutes

    If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    touchEXPERT OPINIONS

    Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchPANEL DISCUSSION

    Immunogenicity of immune checkpoint inhibitors: What are the implications for clinical practice?

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Aditya Bardia, SABCS 2021: Results of EMERALD Phase III Trial

    GO TO HUB
    Steenbruggen_T.png

    CONFERENCE HUB

    Tessa Steenbruggen, ESMO 2018 – High-dose Chemotherapy and Haematopoietic Stem Cell Transplantation in Triple-negative Breast Cancer

    GO TO HUB

    JOURNALS

    Sequencing of Therapy in Breast Cancer

    GO TO ARTICLE

    JOURNALS

    Practical Considerations in Bone Metastases in Breast Cancer

    GO TO ARTICLE

    Topics covered in this activity

    Breast Cancer / Immunotherapy
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This activity is funded by:

    an independent medical education grant from Merck Sharp & Dohme LLC.

    This activity is jointly provided by USF Health and touchIME.

    touchIME is an EBAC® accredited provider.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Date of original release: 25 June 2025. Date credits expire: 25 June 2026.

    EBAC®

    touchIME is an EBAC® accredited provider since 2023.

    In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals outside the UK.

    Date of original release: 25 June 2025. Date credits expire: 25 June 2027.

    Claim Credit
    touchEXPERT FOCUS
    Multidisciplinary management of TNBC: Integrating immunotherapies for early and metastatic disease
    0.75 CE/CME credit
    Question 1/5
    Based on the ESMO and NCCN guidelines, in which of the following early-stage TNBC settings would you consider a neoadjuvant/preoperative regimen that includes systemic immunotherapy?

    c, clinical classification; ESMO, European Society for Medical Oncology; N, regional lymph nodes; NCCN, National Comprehensive Cancer Network®; T, primary tumour; TNBC, triple-negative breast cancer.

    For early-stage TNBC ≥cT2 or N+, ESMO guidelines recommend 6–8 cycles of taxane + carboplatin followed by pembrolizumab + AC/EC (I, A).1 NCCN guidelines recommend preoperative pembrolizumab + carboplatin + paclitaxel, followed by preoperative pembrolizumab + AC/EC for all patients with stage II or III TNBC (category 1).2

    Abbreviations

    AC, doxorubicin + cyclophosphamide; c, clinical classification; EC, epirubicin + cyclophosphamide; ESMO, European Society for Medical Oncology; N, regional lymph nodes; NCCN, National Comprehensive Cancer Network®; T, primary tumour; TNBC, triple-negative breast cancer.

    References

    1. Loibl S, et al. Ann Oncol. 2024;35:159–82.
    2. NCCN Clinical Practice Guidelines in Oncology. Breast cancer. Version 4.2025 – April 17, 2025. Available at: www.NCCN.org (accessed 30 May 2025).
    Question 2/5
    Your patient with early-stage gBRCA1/2 WT TNBC (cT3 N+) has a pCR following neoadjuvant immunotherapy + ChT, followed by surgery. Based on ESMO and NCCN guidelines, what adjuvant treatment regimen would you select for this patient?

    AC, doxorubicin + cyclophosphamide; c, clinical classification; ChT, chemotherapy; EC, epirubicin + cyclophosphamide; ESMO, European Society For Medical Oncology; gBRCA1/2, germline BRCA1/2; N, regional lymph nodes; nab, nanoparticle albumin-bound; NCCN, National Comprehensive Cancer Network®; pCR, pathologic complete response; T, primary tumour; TNBC, triple-negative breast cancer; WT, wildtype.

    For cT1c–T4 or N+ early-stage TNBC, ESMO guidelines recommend 9 cycles of pembrolizumab monotherapy regardless of pCR status following surgery (± locoregional radiotherapy) if pembrolizumab was also received preoperatively (I, A).1 NCCN guidelines recommend adjuvant pembrolizumab monotherapy for all patients with stage II or III TNBC who received preoperative pembrolizumab + ChT (category 1).2

    Abbreviations

    c, clinical classification; ESMO, European Society For Medical Oncology; N, regional lymph nodes; NCCN, National Comprehensive Cancer Network®; pCR, pathologic complete response; T, primary tumour; TNBC, triple-negative breast cancer.

    References

    1. Loibl S, et al. Ann Oncol. 2024;35:159–82.
    2. NCCN Clinical Practice Guidelines in Oncology. Breast cancer. Version 4.2025 – April 17, 2025. Available at: www.NCCN.org (accessed 30 May 2025).
    Question 3/5
    Your patient has confirmed de novo mTNBC. Biomarker test results show that the tumour is PD-L1+ and gBRCA1/2m. Based on NCCN and ESMO guidelines, what first-line treatment option would you select for your patient?

    ChT, chemotherapy; ESMO, European Society For Medical Oncology; gBRCA1/2m, germline BRCA1/2 mutant; mTNBC, metastatic triple-negative breast cancer; NCCN, National Comprehensive Cancer Network®; PD-L1, programmed death-ligand 1.

    ESMO guidelines recommend first-line pembrolizumab + ChT (category I, A) or atezolizumab + ChT (category II, B) for PD-L1+ mTNBC.1 NCCN guidelines similarly recommend first-line pembrolizumab + ChT if PD-L1+, regardless of gBRCA1/2m status (category 1).2 Both ESMO and NCCN recommend that, if PD-L1–, the treatment decision is based on gBRCA1/2m status.1,2

    Abbreviations

    ChT, chemotherapy; ESMO, European Society For Medical Oncology; gBRCA1/2m, germline BRCA1/2 mutation; mTNBC, metastatic triple-negative breast cancer; NCCN, National Comprehensive Cancer Network®; PD-L1, programmed death-ligand 1.

    References

    1. Gennari A, et al. Ann Oncol. 2021;32:1475–95. ESMO Metastatic Breast Cancer Living Guidelines, v1.2 April 2025.
    2. NCCN Clinical Practice Guidelines in Oncology. Breast cancer. Version 4.2025 – April 17, 2025. Available at: www.NCCN.org (accessed 30 May 2025).
    Question 4/5
    Which statement best describes the difference in OS, reported in IMpassion130, observed with first-line atezolizumab + ChT vs placebo + ChT in patients with mTNBC?

    ChT, chemotherapy; ITT, intent-to-treat; mTNBC, metastatic triple-negative breast cancer; OS, overall survival; PD-L1, programmed death-ligand 1.

    The final OS analysis of IMpassion130 (data cut-off 14 April 2020) demonstrated a non-significant improvement in median OS in the ITT population with atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel (21.0 months vs 18.7 months; HR 0.87; 95% CI 0.75–1.02; p=0.077) in patients with unresectable locally advanced or mTNBC.

    Abbreviations

    CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; OS, overall survival; mTNBC, metastatic triple-negative breast cancer.

    Reference

    Emens LA, et al. Ann Oncol. 2021;32:983–93.

    Question 5/5
    Your patient experienced grade 2 pneumonitis while receiving immunotherapy for TNBC. Treatment was withheld and steroids promptly administered. Their symptoms resolved, pneumonitis improved to grade 1 and steroids were tapered 8 weeks after initiation. What would be the next step for this patient?

    TNBC, triple-negative breast cancer.

    Early detection and effective management of immune-related side effects is essential to avoid escalation of events to grade ≥3.1,2 Immunotherapy should be withheld in patients with symptomatic (grade 2) immunotherapy-related pneumonitis and corticosteroids prescribed.2–4 After clinical improvement to grade ≤1 (ASCO, NCCN)2,4 or grade <1 (ESMO),3 corticosteroid tapering should be initiated, over 4–6 weeks.2–4 Immunotherapy rechallenge can be considered once clinical improvement to grade ≤1 (ASCO, NCCN)2,4 or upon complete resolution of symptoms (ESMO),3 with close monitoring.3,4

    Abbreviations

    ASCO, American Society of Clinical Oncology; ESMO, European Society For Medical Oncology; NCCN, National Comprehensive Cancer Network®.

    References

    1. Ikeda T, et al. J Pharm Health Care Sci. 2024;10:78.
    2. Schneider BJ, et al. J Clin Oncol. 2021;39:4073–126.
    3. Haanen J, et al. Ann Oncol. 2022;33:1217–38.
    4. NCCN Clinical Practice Guidelines in Oncology. Management of immunotherapy-related toxicities. Version 1.2025 – December 20, 2024. Available at: www.NCCN.org (accessed 30 May 2025).
    Back to Activity

    You may also be interested in...

    touchEXPERT FOCUS

    Multidisciplinary management of TNBC: Integrating immunotherapies for early and metastatic disease

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Claudine Isaacs, SABCS 2022: Cemiplimab plus REGN3767 in HER2-negative breast cancer: The I-SPY2 trial

    GO TO HUB

    CONFERENCE HUB

    Oleg Gluz, ESMO 2022: Analysis of ADAPT and ADAPTcycle trials – Endocrine therapy response in breast cancer

    GO TO HUB

    touchCONGRESS

    HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the SABCS 2019?

    LAUNCH ACTIVITY

    JOURNALS

    PARP Inhibitors may be Beneficial in a Broader Range of Patients

    GO TO ARTICLE

    JOURNALS

    Developments in Breast Cancer Treatment – Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Inhibitors

    GO TO ARTICLE
    This activity is funded by:

    an independent medical education grant from Merck Sharp & Dohme LLC.

    This activity is jointly provided by USF Health and touchIME.

    touchIME is an EBAC® accredited provider.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Date of original release: 25 June 2025. Date credits expire: 25 June 2026.

    EBAC®

    touchIME is an EBAC® accredited provider since 2023.

    In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals outside the UK.

    Date of original release: 25 June 2025. Date credits expire: 25 June 2027.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup